Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity

MT Newswires Live

03/19

Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.

The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.

The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2620941432"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620941432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620941432?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620941432","market":"sh","top_or_hot":-1,"title":"Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity","media":"MT Newswires Live","content":"<html><body><p> Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.</p><p>The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.</p><p>The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyntara Receives Nearly AU$2 Million Milestone Payment from UK Charity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-19 09:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.</p><p>The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.</p><p>The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620941432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620941432","pubTimestamp":1773883147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syntara  received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","SNT.AU":"Syntara Ltd"},"translate_title":"Syntara收到英国慈善机构近200万澳元的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNT.AU":1},"content_text":"Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}